DOMINIC - Non-interventional Study about Dose modifications of Docetaxel in the therapy of metastatic castration resistant Prostate Cancer

DOMINIC - Non-interventional Study about Dose modifications of Docetaxel in the therapy of metastatic castration resistant Prostate Cancer - DOMINIC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00007955

Enrollment

600

Registered

2015-03-30

Start date

2015-03-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Patients with metastatic castration resistant Prostate Cancer where therapy with Docetaxel is indicated. Efficacy will be assessed through routine laboratory at each cycle up to cycle No. 8.

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: -histologically confirmed prostate cancer -Prostate cancer is castration resistance -By Hand signed and dated consent

Exclusion criteria

Exclusion criteria: - Contraindications to the use of oxaliplatin LIV Pharma according to the SmPC. - The patient is participating in a study at the same time.

Design outcomes

Primary

Measure	Time frame
Progressioin during therapy via clinical assessment or imaging.	—

Secondary

Measure	Time frame
Lack of Tolerability.	—

Countries

Germany

Contacts

Public ContactBurkard Heckelbacher

Datafaber GbR

heckelbacher@datafaber.de+49 8161 885 107

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026